Esperion Therapeutics, Inc.

NASDAQ:ESPRHealthcare · Biotechnology

Mkt Cap-

Float234.07M

Shares O/S-

Inst Own-

Dilution

Mkt Cap-

Float234.07M

O/S-

Inst Own-

Dilution

NASDAQ:ESPR

MCap-

Float234.07M

O/S-

Inst Own-

Dilution

Historical Data

Date	Open	High	Low	Close	Volume

Key Metrics

Market Cap--

Enterprise Value--

P/E Ratio--

Est. Net Cash/Share--

Institutional Ownership--

SectorHealthcare

IndustryBiotechnology

ExchangeNASDAQ

Country

IPO DateJun 26, 2013

Shares Outstanding-

Float234.07M

Company Overview

Esperion Therapeutics, Inc. operates as a pharmaceutical firm, concentrating on the development and commercialization of treatments for individuals with high levels of low-density lipoprotein (LDL) cholesterol.

The company's flagship pharmaceutical products are NEXLETOL (bempedoic acid) and NEXLIZET (a tablet combining bempedoic acid and ezetimibe), prescribed for managing conditions such as atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.

In addition, Esperion maintains a licensing and collaborative partnership with Daiichi Sankyo Europe GmbH, alongside an agreement with Serometrix to acquire rights to an oral, small molecule PCSK9 inhibitor program. Established in 2008, the company's corporate offices are situated in Ann Arbor, Michigan.

Leadership

Mary P. McGowan, M.D.

Chief Medical Officer

Narendra D. Lalwani, Ph.D., FAHA, DABT

Executive Vice President, Research & Development, and Chief Operating Officer

Roger S. Newton, Ph.D., FAHA

Executive Chairman and Chief Scientific Officer

Tim M. Mayleben

President and Chief Executive Officer

Employees

294

Country

Sector

Healthcare

Website

esperion.com

Analyst Coverage

ConsensusHold

Price Target

No price targets available

Ratings Distribution

BUY

HOLD

SELL

TOTAL25

Insider Trading

Insider	Title	Type	Shares	Value	Date
Fischer Seth H. Z.	Director	Withholding/Transfer	44.0K	--	Jul 13, 2026
Fischer Seth H. Z.	Director	Withholding/Transfer	21.0K	--	Jul 13, 2026
Shepard Jay	Director	Withholding/Transfer	44.0K	--	Jul 13, 2026
Shepard Jay	Director	Withholding/Transfer	32.5K	--	Jul 13, 2026
Shepard Jay	Director	Withholding/Transfer	21.0K	--	Jul 13, 2026
CARROLL J MARTIN	Director	Withholding/Transfer	44.0K	--	Jul 13, 2026

Shareholders

Institutional

(168)

Insiderⓘ

(2)

5%+ Owners

(1)

Unattributed (incl. retail)ⓘ

Top Shareholders

Name	Shares	%	Source
GLAZER CAPITAL, LLC	22.4M	--	13F
BlackRock, Inc.	22.1M	--	13F
THE GOLDMAN SACHS GROUP, INC. · net of 13F· joint filing· may incl. warrants· filed Sep 2026	17.2M	6.7%	13G
BlackRock, Inc. · also on 13F· may incl. warrants· filed Nov 2024	14.3M	7.3%	13G
VANGUARD CAPITAL MANAGEMENT LLC	11.4M	--	13F
GOLDMAN SACHS GROUP INC	10.4M	--	13F
STATE STREET CORP	7.3M	--	13F
TWO SIGMA INVESTMENTS, LP	7.1M	--	13F
GEODE CAPITAL MANAGEMENT, LLC	6.6M	--	13F
AQR Arbitrage LLC	6.0M	--	13F